Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29964739 | 1.00 | SIGMAR1 (0.61) | SIGMAR1ATMHRH3ADRA1DADRA1A | |
| SCHEMBL742078 | 0.84 | SIGMAR1 (0.65) | SIGMAR1ATMHRH3ADRA1DADRA1A | |
| SCHEMBL16503899 | 0.81 | SIGMAR1 (0.65) | SIGMAR1ATMHRH3ADRA1DADRA1A | |
| SCHEMBL30538348 | 0.81 | ATM (0.64) | SIGMAR1ATMHRH3ADRA1DADRA1A | |
| SCHEMBL4518944 | 0.80 | HDAC3 (0.56) | ATM | |
| SCHEMBL21145503 | 0.80 | CYP2D6 (0.46) | SIGMAR1HRH3ADRA1DADRA1AADRA1B | |
| SCHEMBL31329795 | 0.80 | L3MBTL1 (0.62) | SIGMAR1ATMHRH3ADRA1DADRA1A | |
| SCHEMBL13790914 | 0.80 | L3MBTL1 (0.62) | SIGMAR1ATMHRH3ADRA1DADRA1A | |
| SCHEMBL9963313 | 0.79 | HRH3 (0.52) | SIGMAR1HRH3ADRA1DADRA1AADRA1B | |
| SCHEMBL2588053 | 0.79 | SIGMAR1 (0.66) | SIGMAR1ATMHRH3ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868763-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2018-01-16 | — | — | US | disclosed |
| US-9701711-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-11 | — | — | US | disclosed |
| US-9701711-B2 | Modulators of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-11 | — | — | US | disclosed |
| US-20150038402-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | UNIV QUEENSLAND (AU) | 2015-02-05 | — | — | US | disclosed |
| US-8927503-B2 | Modulations of protease activated receptors | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-01-06 | — | — | US | disclosed |
| US-8901085-B2 | — | — | 2014-12-02 | — | — | US | disclosed |
| US-20140315796-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2014-10-23 | — | — | US | disclosed |
| US-20130184226-A1 | MODULATIONS OF PROTEASE ACTIVATED RECEPTORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2013-07-18 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | ACADIA PHARMACEUTICALS INC. (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184226-A1 | MODULATIONS OF PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | SIGMAR1 2075/4885ATM 3361/4885HRH3 461/4885 |
| US-20070213359-A1 | BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF | GIPR, GHSR, GHRHR | SIGMAR1 175/4885ATM 4514/4885HRH3 527/4885 |
| US-20140315796-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | SIGMAR1 1537/4885ATM 3426/4885HRH3 1914/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | SIGMAR1 152/4885ATM 3949/4885HRH3 250/4885 |
| US-20150038402-A1 | MODULATORS OF PROTEASE ACTIVATED RECEPTORS | F2R, F2RL1, F2RL3 | SIGMAR1 1668/4885ATM 3491/4885HRH3 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.